Alcobra (ADHD) seeking strategic alternatives

  • June 23, 2017

Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that its Board of Directors is conducting a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its development assets and cash resources.

Update(s):

September 27, 2017: Alcobra Ltd. (ADHD) and Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, today announced the signing of a definitive agreement to merge the two companies in an all-stock transaction